Perspective Therapeutics, Inc. (CATX)
XASE:CATX
Want to see CATX full AI Analyst Report?
CATX Stock Chart & Stats
$4.20
-$0.13(-3.36%)
At close: 4:00 PM EST
$4.20
-$0.13(-3.36%)
Day’s Range― - ―
52-Week Range$1.96 - $6.16
Previous CloseN/A
Volume311.62K
Average Volume (3M)1.43M
Market Cap
$338.72M
Enterprise Value$253.01M
Total Cash (Recent Filing)$270.93M
Total Debt (Recent Filing)$2.62M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Aug 18, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-26.44
Shares Outstanding114,046,196
10 Day Avg. Volume1,496,327
30 Day Avg. Volume1,425,588
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-2.13
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue440.02
Enterprise Value/Gross Profit-122.88
Enterprise Value/Ebitda-2.29
Forecast
1Y Price Target
$12.82Price Target Upside205.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.11
Revenue Forecast (FY)$389.33K
Bulls Say, Bears Say
Bulls Say
Strong Liquidity And RunwayA sizable cash balance and recent equity raise provide durable financial cushion to fund multi-cohort Phase 1/2a programs and manufacturing build-out. This reduces near-term financing pressure, supporting execution of clinical and capacity milestones over the next 12–18 months.
Encouraging Interim Clinical DataConsistent early efficacy and a tolerable safety profile across lead candidates materially de-risks development paths. Durable responses and low high-grade toxicity improve chances for registration-enabling strategies, partner interest, and longer-term commercial viability if confirmed in later trials.
Vertical Manufacturing And IP EstateOwning supply chain, proprietary chelators and planned regional manufacturing supports reliable product availability, faster hospital delivery, and control over unit economics. This vertical model and IP coverage create durable operational advantages versus asset-light peers.
Bears Say
High Cash BurnSustained negative operating and free cash flow implies ongoing reliance on capital markets or partnerships to fund trials and plant construction. Even with current cash, persistent burn narrows strategic optionality and raises dilution or funding-timing risk if milestones slip or markets tighten.
Minimal Current Revenues, Large LossesA tiny revenue base and substantial recurring losses mean operations are not self-sustaining. Until commercial products or partnership milestones materialize, the company will remain loss-making, constraining reinvestment capacity and increasing dependency on external funding.
Execution And Trial Outcome RiskPrograms are in Phase 1/2a where pivotal outcomes, dosing, registration strategy, and scale-up remain uncertain. Clinical, regulatory, or manufacturing setbacks would materially affect timelines and commercial prospects, making fundamental upside contingent on successful trial progression.
Perspective Therapeutics News
CATX FAQ
What was Perspective Therapeutics, Inc.’s price range in the past 12 months?
Perspective Therapeutics, Inc. lowest stock price was $1.96 and its highest was $6.16 in the past 12 months.
What is Perspective Therapeutics, Inc.’s market cap?
Perspective Therapeutics, Inc.’s market cap is $338.72M.
When is Perspective Therapeutics, Inc.’s upcoming earnings report date?
Perspective Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 66 days.
How were Perspective Therapeutics, Inc.’s earnings last quarter?
Perspective Therapeutics, Inc. released its earnings results on May 11, 2026. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.294 by $0.044.
Is Perspective Therapeutics, Inc. overvalued?
According to Wall Street analysts Perspective Therapeutics, Inc.’s price is currently Undervalued.
Does Perspective Therapeutics, Inc. pay dividends?
Perspective Therapeutics, Inc. does not currently pay dividends.
What is Perspective Therapeutics, Inc.’s EPS estimate?
Perspective Therapeutics, Inc.’s EPS estimate is -0.26.
How many shares outstanding does Perspective Therapeutics, Inc. have?
Perspective Therapeutics, Inc. has 114,046,196 shares outstanding.
What happened to Perspective Therapeutics, Inc.’s price movement after its last earnings report?
Perspective Therapeutics, Inc. reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.294. Following the earnings report the stock price went down -2.835%.
Which hedge fund is a major shareholder of Perspective Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CATX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Perspective Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.82 (205.19% Upside)
$12.82 (205.19% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 80.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.45%
12-Months-Change
Fundamentals
Return on Equity
-41.84%
Trailing 12-Months
Asset Growth
24.72%
Trailing 12-Months
Company Description
Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
CATX Stock 12 Month Forecast
Average Price Target
$12.82
▲(205.19% Upside)
Technical Analysis
Ownership Overview
1.63% Insiders
7.55% Mutual Funds
35.26% Other Institutional Investors
45.68% Public Companies and
Individual Investors